COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrit
Ongoing trial of crofelemer in UAE shows reduction in parenteral support for pediatric intestinal failure patients. Breakthrough in MVID and SBS-IF treatment -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. (NASDAQ:JAGX) granted RSUs to new employees effective October 20, 2025. RSUs vest over one year. The Company focuses on developing prescription medicines from rainforest plants for gastrointestinal distress -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals provides update on ongoing clinical trial for the treatment of MVID in pediatric patients, showing significant reduction in parenteral support in UAE. FDA advice sought for study advancement
